Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous MSCs for No-Option Critical Limb Ischemia
NCT03455335Phase 1Completed
- Sponsor
- University of Galway
- Start
- Mar 2015
- Primary completion
- Oct 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous bone marrow derived mesenchymal stromal cells in critical limb ischemia (CLI) (3 cohorts), sponsored by University of Galway. Primary endpoints: Serious Adverse Events at 12 months and Severity of Serious Adverse Events at 12 months. Started Mar 2015; status: completed.
02
Drugs
autologous bone marrow derived mesenchymal stromal cells
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT03455335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03455335.